UBS Group’s Cantel Medical Corporation CMD Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2021
Q2 | – | Sell |
-464,483
| Closed | -$37.1M | – | 10337 |
|
|
2021
Q1 | $37.1M | Buy |
464,483
+404,913
| +680% | +$31.6M | 0.01% | 1027 |
|
|
2020
Q4 | $4.7M | Buy |
59,570
+239
| +0.4% | +$14K | ﹤0.01% | 2511 |
|
|
2020
Q3 | $2.61M | Buy |
59,331
+9,645
| +19% | +$475K | ﹤0.01% | 2801 |
|
|
2020
Q2 | $2.2M | Sell |
49,686
-32,511
| -40% | -$1.21M | ﹤0.01% | 2781 |
|
|
2020
Q1 | $2.95M | Buy |
82,197
+13,381
| +19% | +$761K | ﹤0.01% | 2394 |
|
|
2019
Q4 | $4.88M | Buy |
68,816
+6,230
| +10% | +$452K | ﹤0.01% | 2622 |
|
|
2019
Q3 | $4.68M | Sell |
62,586
-6,520
| -9% | -$553K | ﹤0.01% | 2445 |
|
|
2019
Q2 | $5.57M | Sell |
69,106
-6,000
| -8% | -$422K | ﹤0.01% | 2226 |
|
|
2019
Q1 | $5.02M | Buy |
75,106
+4,546
| +6% | +$344K | ﹤0.01% | 2201 |
|
|
2018
Q4 | $5.25M | Sell |
70,560
-18,881
| -21% | -$1.56M | ﹤0.01% | 2104 |
|
|
2018
Q3 | $8.23M | Buy |
89,441
+16,414
| +22% | +$1.56M | ﹤0.01% | 1937 |
|
|
2018
Q2 | $7.18M | Buy |
73,027
+5,692
| +8% | +$637K | ﹤0.01% | 2018 |
|
|
2018
Q1 | $7.5M | Buy |
67,335
+3,081
| +5% | +$345K | ﹤0.01% | 1938 |
|
|
2017
Q4 | $6.61M | Buy |
64,254
+4,834
| +8% | +$482K | ﹤0.01% | 2078 |
|
|
2017
Q3 | $5.6M | Buy |
59,420
+7,211
| +14% | +$569K | ﹤0.01% | 2098 |
|
|
2017
Q2 | $4.07M | Sell |
52,209
-42,212
| -45% | -$3.17M | ﹤0.01% | 2342 |
|
|
2017
Q1 | $7.56M | Sell |
94,421
-3,833
| -4% | -$305K | ﹤0.01% | 1728 |
|
|
2016
Q4 | $7.74M | Buy |
98,254
+5,279
| +6% | +$410K | ﹤0.01% | 1713 |
|
|
2016
Q3 | $7.25M | Buy |
92,975
+46,919
| +102% | +$3.4M | ﹤0.01% | 1685 |
|
|
2016
Q2 | $3.17M | Sell |
46,056
-6,574
| -12% | -$453K | ﹤0.01% | 2384 |
|
|
2016
Q1 | $3.76M | Buy |
52,630
+1,348
| +3% | +$84.6K | ﹤0.01% | 2119 |
|
|
2015
Q4 | $3.19M | Sell |
51,282
-33
| -0.1% | -$2.01K | ﹤0.01% | 2367 |
|
|
2015
Q3 | $2.91M | Sell |
51,315
-14,135
| -22% | -$748K | ﹤0.01% | 2413 |
|
|
2015
Q2 | $3.51M | Buy |
65,450
+7,207
| +12% | +$351K | ﹤0.01% | 2427 |
|
|
2015
Q1 | $2.77M | Buy |
58,243
+5,162
| +10% | +$228K | ﹤0.01% | 2623 |
|
|
2014
Q4 | $2.3M | Buy |
+53,081
| New | +$2.17M | ﹤0.01% | 2772 |
|
UBS Group's CMD Position: Q2 2021 in Review
UBS Group sold out of Cantel Medical Corporation (CMD) in Q2 2021, closing a stake of 464,483 shares — an estimated $37.1M sold.
UBS Group first reported a position in CMD in Q4 2014 and held it in 26 quarters. The position peaked at $37.1M in Q1 2021. 0 funds tracked by Wall St. Rank hold CMD as of Q2 2021.
- UBS Group reported no remaining Cantel Medical Corporation position as of Q2 2021 after selling out during the quarter.
- UBS Group sold 464,483 Cantel Medical Corporation shares in Q2 2021, an estimated $37.1M.
- UBS Group first reported a position in Cantel Medical Corporation in Q4 2014 and held it in 26 quarters.
- UBS Group's Cantel Medical Corporation position peaked at $37.1M in Q1 2021.
- 0 funds tracked by Wall St. Rank held Cantel Medical Corporation as of Q2 2021.
Based on UBS Group's 13F filing for Q2 2021, filed 13 Aug 2021.